Assessing the oseltamivir-induced resistance risk and implications for influenza infection control strategies
Journal
Infection and Drug Resistance
Journal Volume
10
Pages
215-226
Date Issued
2017
Author(s)
Abstract
BACKGROUND: Oseltamivir-resistant mutants with higher drug resistance rates and low trans-mission fitness costs have not accounted for influenza (sub)type viruses. Predicting the impacts of neuraminidase inhibitor therapy on infection rates and transmission of drug-resistant viral strains requires further investigation. OBJECTIVES: The purpose of this study was to assess the potential risk of oseltamivir-induced resistance for influenza A (H1N1) and A (H3N2) viruses. MATERIALS AND METHODS: An immune-response-based virus dynamic model was used to best fit the oseltamivir-resistant A (H1N1) and A (H3N2) infection data. A probabilistic risk assessment model was developed by incorporating branching process-derived probability distribution of resistance to estimate oseltamivir-induced resistance risk. RESULTS: , respectively. Antiviral drugs must be administrated within 1-1.5 days for A (H1N1) and 2-2.5 days for A (H3N2) virus infections to limit viral production. CONCLUSION: Probabilistic risk assessment of antiviral drug-induced resistance is crucial in the decision-making process for preventing influenza virus infections.
SDGs
Type
journal article